Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.5.4.4 (
adenosine deaminase
)
5,136
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The expression of the enzyme
adenosine deaminase
(
ADA
) decreases in the course of the differentiation of the human promyelocytic leukemic cell line HL-60, dependent on the pathway chosen. Differentiation to monocytes as induced by the phorbol ester TPA leads to a 50% reduction of enzyme activity. Induction to myeloid cells as induced by DMSO has a slower and less extensive (75% remaining activity) effect. The reduction in
ADA
enzymatic activity is preceded by a 5-10 fold reduction in
ADA
-specific mRNA which is also more rapid during TPA-induced differentiation. In contrast,
c-myc mRNA
expression is both in TPA- and DMSO-induced differentiation reduced to less then 5% of its initial level within 4h. Nuclear run-on analysis revealed that the reduction of c-myc-mRNA expression during both TPA- and DMSO-induced differentiation could be ascribed to the abolition of transcription of the third exon, whereas no change in the transcription of the first exon could be observed. No change could be detected in the rate of transcription of either the 5' and 3' parts of the
ADA
gene during TPA- and DMSO-induced differentiation, indicating that the expression of the
ADA
gene in HL-60 is controlled at a posttranscriptional level.
...
PMID:Adenosine deaminase mRNA expression is regulated posttranscriptionally during differentiation of HL-60 cells. 330 3